Edition:
United States

Syneron Medical Ltd (ELOS.OQ)

ELOS.OQ on NASDAQ Stock Exchange Global Select Market

8.55USD
20 Jan 2017
Change (% chg)

$-0.05 (-0.58%)
Prev Close
$8.60
Open
$8.60
Day's High
$8.65
Day's Low
$8.55
Volume
10,110
Avg. Vol
19,666
52-wk High
$9.05
52-wk Low
$6.13

ELOS.OQ

Chart for ELOS.OQ

About

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies,... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $296.78
Shares Outstanding(Mil.): 34.71
Dividend: --
Yield (%): --

Financials

  ELOS.OQ Industry Sector
P/E (TTM): 99.84 33.72 30.38
EPS (TTM): 0.09 -- --
ROI: 1.39 13.18 14.86
ROE: 1.44 16.79 16.28

BRIEF-Syneron Medical posts Q3 GAAP EPS of $0.02

* Syneron Medical reports third quarter 2016 revenue of $71.5 million

Nov 09 2016

BRIEF-Syneron Candela says FDA clears its cellulite treatment

* Syneron candela announces FDA clearance of Profound SubQ to improve appearance of cellulite, as supported by long term data Source text for Eikon: Further company coverage:

Nov 08 2016

BRIEF-Craig Drill reports 5.17 pct passive stake in Syneron Medical

* Craig Drill reports 5.17 pct passive stake in Syneron Medical Ltd as of October 17 - sec filing Source text : http://bit.ly/2e014mh Further company coverage:

Oct 17 2016

BRIEF-Syneron Medical strengthens senior management and reports preliminary Q3 revenue

* Syneron Medical strengthens senior management and announces preliminary third quarter 2016 revenue

Oct 17 2016

BRIEF-Syneron Medical Q2 non-gaap EPS $0.09

Aug 4 Syneron Medical Reports Second Quarter 2016 Revenue Of $75.0 Million And Non

Aug 04 2016

BRIEF-Syneron Medical Ltd says PicoWay Picosecond laser receives U.S. FDA clearance for ultra-short 785nm wavelength

* Syneron Candela's Picoway Picosecond laser receives U.S. FDA clearance for ultra-short 785nm wavelength Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 25 2016

Earnings vs. Estimates